Industry / India
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Glenmark To Focus On Original Drugs
March 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Indian drugmaker Glenmark Pharmaceuticals is looking to boost growth by spinning off its generics and active pharmaceutical ingredient (API) businesses, concentrating on original R&D and branded formulations. The company has also established a new subsidiary in Romania, boosting its presence in Central and Eastern Europe (CEE). BMI endorses these developments as the former will facilitate strategic investments, while the latter will result in increased